Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;38 Suppl 1(Suppl 1):S41-7.
doi: 10.1007/s00259-011-1769-1. Epub 2011 Apr 12.

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

George Sgouros  1 , Robert F Hobbs, Francis B Atkins, Douglas Van Nostrand, Paul W Ladenson, Richard L Wahl
Affiliations
Review

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

George Sgouros et al. Eur J Nucl Med Mol Imaging. 2011 May.

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, (124)I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of (124)I PET/CT on thyroid cancer therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None.

Figures

Fig. 1
Fig. 1
Representative coronal slices of absorbed dose (D) maps of two different data sets: torso (measured) (a) and head (modeled) (b). In modeled calculation, average tumor activity concentration was placed in two tumor-associated volumes of interest defined using CT; voxels representing normal brain were assigned average (background) brain activity concentration. 3D-RD was then executed using these two as source regions of uniform activity irradiating normal brain. In this way, possible calculation artifacts associated with high tumor count–density gradients were avoided. Both images are viewed anteriorly
Fig. 2
Fig. 2
Dose-volume histograms (and BED histograms) for the lung volume of interest voxels. The blue histograms represent normal lung tissue, while the red lines are tumor tissue. The thick vertical lines show the voxel averages
Fig. 3
Fig. 3
a Dose-volume histograms (DVHs) for normal organs are shown with the voxel averaged absorbed dose (blue dotted line) and the mean absorbed dose obtained from a whole-organ contour (red dotted line) superimposed on the DVHs. b The DVH for two tumors receiving a mean absorbed dose of 110 Gy with an EUD of 16.8 Gy and a mean absorbed dose of 61.5 Gy with an EUD of 28.4 Gy. c Transverse and coronal cross sections depicting absorbed dose images of the two tumors in b
Fig. 3
Fig. 3
a Dose-volume histograms (DVHs) for normal organs are shown with the voxel averaged absorbed dose (blue dotted line) and the mean absorbed dose obtained from a whole-organ contour (red dotted line) superimposed on the DVHs. b The DVH for two tumors receiving a mean absorbed dose of 110 Gy with an EUD of 16.8 Gy and a mean absorbed dose of 61.5 Gy with an EUD of 28.4 Gy. c Transverse and coronal cross sections depicting absorbed dose images of the two tumors in b
See this image and copyright information in PMC

References

    1. Hellman S, Devita VT, Rosenberg SA. Cancer: principles & practice of oncology. 6. Philadelphia: Lippincott Williams and Wilkins; 2001. Principles of cancer management: radiation therapy; pp. 265–88.
    1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214. - PubMed
    1. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12 (2):121–34. - PubMed
    1. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radio-iodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15 (12):1321–31. - PubMed
    1. Driedger AA, Quirk S, McDonald TJ, Ledger S, Gray D, Wall W, et al. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure. Clin Nucl Med. 2006;31(8):454–7. - PubMed

Publication types

MeSH terms